Davis ID - Search Results

1

Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer.

Kwan EM, Fettke H, Crumbaker M, Docanto MM, To SQ, Bukczynska P, Mant A, Ng N, Foroughi S, Graham LK, Haynes AM, Azer S, Lim LE, Segelov E, Mahon K, Davis ID, Parente P, Pezaro C, Todenhöfer T, Sathianathen N, Hauser C, Horvath LG, Joshua AM, Azad AA. Kwan EM, et al. Among authors: davis id. Transl Androl Urol. 2021 Apr;10(4):1688-1699. doi: 10.21037/tau-20-1444. Transl Androl Urol. 2021. PMID: 33968657 Free PMC article.

2

Rational approaches to human cancer immunotherapy.

Davis ID, Jefford M, Parente P, Cebon J. Davis ID, et al. J Leukoc Biol. 2003 Jan;73(1):3-29. doi: 10.1189/jlb.0502261. J Leukoc Biol. 2003. PMID: 12525559 Review.

3

Targeted therapies in the treatment of renal cell carcinoma.

Pezaro C, Davis ID. Pezaro C, et al. Among authors: davis id. Curr Med Chem. 2008;15(12):1166-74. doi: 10.2174/092986708784310440. Curr Med Chem. 2008. PMID: 18473811 Review.

4

An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.

Pezaro C, Rosenthal MA, Gurney H, Davis ID, Underhill C, Boyer MJ, Kotasek D, Solomon B, Toner GC. Pezaro C, et al. Among authors: davis id. Am J Clin Oncol. 2009 Aug;32(4):338-41. doi: 10.1097/COC.0b013e31818b946b. Am J Clin Oncol. 2009. PMID: 19363437 Clinical Trial.

5

Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.

Svobodová S, Browning J, MacGregor D, Pollara G, Scolyer RA, Murali R, Thompson JF, Deb S, Azad A, Davis ID, Cebon JS. Svobodová S, et al. Among authors: davis id. Eur J Cancer. 2011 Feb;47(3):460-9. doi: 10.1016/j.ejca.2010.09.042. Epub 2010 Nov 4. Eur J Cancer. 2011. PMID: 21115342

6

Urothelial cancers: using biology to improve outcomes.

Pezaro C, Liew MS, Davis ID. Pezaro C, et al. Among authors: davis id. Expert Rev Anticancer Ther. 2012 Jan;12(1):87-98. doi: 10.1586/era.11.195. Expert Rev Anticancer Ther. 2012. PMID: 22149435 Review.

7

USANZ: Time-trends in use and impact on outcomes of perioperative chemotherapy in patients treated with radical cystectomy for urothelial bladder cancer.

Liew MS, Azad A, Tafreshi A, Eapen R, Bolton D, Davis ID, Sengupta S. Liew MS, et al. Among authors: davis id. BJU Int. 2013 Nov;112 Suppl 2:74-82. doi: 10.1111/bju.12384. BJU Int. 2013. PMID: 24127680

8

A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.

Lau DK, Andrews MC, Turner N, Azad AA, Davis ID, Cebon JS. Lau DK, et al. Among authors: davis id. Melanoma Res. 2014 Apr;24(2):144-9. doi: 10.1097/CMR.0000000000000036. Melanoma Res. 2014. PMID: 24463460

9

Prostate cancer: measuring PSA.

Pezaro C, Woo HH, Davis ID. Pezaro C, et al. Among authors: davis id. Intern Med J. 2014 May;44(5):433-40. doi: 10.1111/imj.12407. Intern Med J. 2014. PMID: 24816306 Review.

10

Lymphadenectomy with radical cystectomy at an Australian tertiary referral institution: time trends and impact on oncological outcomes.

Eapen R, Liew MS, Tafreshi A, Papa N, Lawrentschuk N, Azad A, Davis ID, Bolton D, Sengupta S. Eapen R, et al. Among authors: davis id. ANZ J Surg. 2015 Jul-Aug;85(7-8):535-9. doi: 10.1111/ans.12772. Epub 2014 Jul 14. ANZ J Surg. 2015. PMID: 25040795

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

316 results

Search Page

Filters